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Abstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine 
(galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients 
with mild-to-moderate Alzheimer’s disease (AD). Except for predicted differences in (Cmax) and 
tmax, comparable doses of once daily galantamine-ER and regular, immediate release galantamine, 
(galantamine-IR), are pharmacologically equivalent. A 24-week randomized, double-blind, 
placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, 
galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination 
[MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly 
better than placebo in terms of cognition, although not with regard to global change. There 
was no difference in drug-related adverse events between galantamine-ER and galantamine-IR. 
Since its release onto the market galantamine-ER has enjoyed wide popularity and a recent 
surveillance study suggests that it has the highest 1-year persistence rate of all the ChEIs.
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Introduction
Alzheimer’s disease and cholinesterase inhibitors
Alzheimer’s disease (AD), a neurodegenerative disorder, is the most common cause of 
dementia in the elderly. Occurring either by itself, or in association with other neuro-
pathological conditions, eg, cerebrovascular disease, cortical Lewy bodies, AD accounts 
for 60% to 80% of cases of dementia.1 Although dementia can occur at any age, it is 
overwhelmingly an affliction of the elderly. By the age of 90 years, over one quarter 
of some United States populations have sufficient cognitive impairment to qualify as 
dementia.2 As more and more people across the world reach advanced age over the next 
decades, AD will inevitably become an even more important social, economic, and 
medical problem. The histological hallmarks of AD are: 1) intraneuronal neurofibrillary 
tangles, which correspond at the ultrastructural level to twisted strands of hyperphos-
phorylated microtubule-associated tau protein and 2) extracellular neuritic, or senile, 
amyloid plaques. The latter consist of aggregates of an insoluble species of amyloid 
beta (Aβ), dystrophic neurites, and microglial cells.3 Although tangles and plaques 
are found in normal individuals, their presence, in large amounts and in characteristic, 
eg, medial temporal, areas of the brain are diagnostic of AD.4 The etiology of AD is 
mostly unknown, but a small proportion of cases, typically of early onset, have clear 
genetic roots and even in sporadic AD, which constitutes the vast bulk of cases, genetic 
risk factors, especially the apolipoprotein E gene allele ε4, play an important role.5Clinical Interventions in Aging 2010:5 
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In recent years, therapeutic efforts have focused on 
developing treatment modalities that either prevent the 
aggregation or dispel the buildup of Aβ.6 Up to this point, 
however, these approaches remain experimental, so that the 
backbone of pharmacological treatment continues to be, for 
all stages of AD, the class of drugs known as cholinesterase 
inhibitors (ChEIs), supplemented, in moderate-to-severe AD, 
by the N-methyl-D-aspartate (NMDA) receptor antagonist 
memantine.7 The rationale for ChEI therapy in AD is the 
“cholinergic hypothesis”.8,9 There is compelling evidence that 
central cholinergic transmission is important for cognition, 
and that cholinergic neurons and pathways, among other 
structures, are disrupted in AD. Cholinergic replacement 
therapy therefore represents a rational approach to treating 
the salient symptoms of the disease. In theory, a number of 
different ways to increase central cholinergic activity exist, 
but the ChEIs, which act by inhibiting acetylcholinesterase, 
the cholinergic degrading enzyme in the synapse, remain, up 
to the present time, the only practical way of achieving this 
goal.10 Although effective, the prototype, physostigmine,11 
and tacrine, the first ChEI specifically developed to treat AD,12 
have excessive adverse effects. As a result, clinicians rely 
mainly on one of three different drugs in this class: donepezil, 
rivastigmine, and galantamine. In common practice ChEIs are 
combined with the NMDA-antagonist memantine in patients 
with moderate-to-severe AD.13
Galantamine-immediate release:  
general observations
Galantamine (Reminyl™ or Razadyne™), an extract of the 
flowers and bulbs of the lily, daffodil, and related plants, 
was the last of the three major ChEIs to be approved by the 
United States Food and Drug Administration (FDA) but the 
first to come off patent and be available in generic form. In 
addition to being a ChEI, galantamine is also believed to 
enhance central neurotransmission by allosteric modulation 
of pre- and post-synaptic nicotinic receptors.14–16 Never-
theless, the clinical efficacy of galantamine is essentially 
equivalent to that of donepezil, a pure acetylcholinesterase 
inhibitor, and the significance of galantamine’s putative 
nictonic modulating effect remains unknown. It has also 
been suggested that ChEIs, considered as a class, provide 
protection against oxidative stress and Aβ toxicity. If so, they 
might potentially modify the course of AD17–19 in addition 
to improving clinical symptoms. These suggestions remain, 
however, speculative.
Galantamine was first formulated in an immediate-release 
(IR), twice daily, preparation. The pivotal trials, published in 
2000 and 2001, compared total daily doses of 16 to 32 mg to 
placebo for periods of 12 to 24 weeks in subjects with mild 
to moderate AD (baseline mini mental state examination 
[MMSE]20 score range, 10 to 24).21–25 As is typical for such 
studies, the main outcomes were cognitive performance 
measured by the Alzheimer’s Disease Assessment Scale-
cognitive subscale (ADAS-cog)26 and global change, mea-
sured by the Clinician Interview-Based Impression of Change 
incorporating Caregiver Information (CIBIC-plus).27 Func-
tion and behavior were also assessed in some of the trials.
Meta-analyses of the results coming from these and other 
trials have concluded that galantamine, in doses within the 
above mentioned range, significantly improves cognitive 
performance and global rating scores for 3 to 6 months.28–30 
However, no statistically significant dose-response effect was 
found. The clinical results obtained with galantamine were 
generally comparable to those of similarly constructed pivotal 
trials of donepezil and rivastigmine in the same population. 
There are not enough, properly designed, “head to head” 
trials for a meaningful, direct comparison of galantamine 
with the other two ChEIs.
Subsequent, long term, non-placebo controlled extension 
trials showed continuing cognitive and functional benefit from 
galantamine-IR for periods of up to 36 months.31,32 In addition, 
subjects with mild to moderate AD receiving galantamine-IR 
as part of a naturalistic study33 and in a controlled study using a 
novel “goal attaining” instrument34 were also shown to benefit 
from treatment. Significant improvement in some, but not 
all, domains was demonstrated in subjects with severe AD 
(MMSE score range, 5–12)35 as well as vascular dementia.36 
However, galantamine failed to reduce conversion to dementia 
in subjects with mild cognitive impairment.37
Galantamine-IR is absorbed rapidly from the gastrointes-
tinal tract and has a relatively brief half-life of approximately 
7 hours.38 Its pharmacokinetic and metabolic profile16 are such 
that it requires twice daily dosing. Furthermore, to cut down 
on possible side effects, it is recommended that it be taken 
with food and that the dosage be slowly raised at 4 week 
intervals, starting at 8 mg/day. A recent study39 suggested that 
galantamine-IR 16 mg/day is the optimal dosage for patients 
with mild AD although some patients with moderate AD may 
get additional benefit from 24 mg/day.
Galantamine-IR has met with widespread acceptance and 
is used extensively the world over in the treatment of AD. The 
twice daily dosing schedule, however, puts it at a disadvantage 
vis-à-vis donepezil, which can be taken orally only once a day. 
Frequency of administration, always an issue in determining 
the acceptability of a medication, is particularly important in Clinical Interventions in Aging 2010:5 
Galantamine-er for treating Alzheimer’s disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
galantamine’s target population. Memory and other cognitive 
impairments obviously impact AD patients’ compliance with 
taking medication, and conversion from a twice daily to once 
daily regimen cuts in half the chances of missing a dose. The 
problem is especially acute for individuals living on their 
own, who must either be left to their own devices in taking 
medication or for whom caregivers must make a special trip 
to monitor medication adherence.40 Such considerations 
led to the effort to develop a once daily, extended-release 
formulation of galantamine for oral use.
Galantamine-extended release
The extended release formulation of galantamine, 
galantamine-ER, is a capsule composed of pellets. While 25% 
of the dose is in an immediate release form, the remaining 
75% is in a controlled release form.41 Before clinical testing, 
it was crucial to demonstrate the general bioequivalence of 
comparable doses of galantamine-ER and galantamine-IR. 
This was accomplished in two ways. The first was a clinical 
study contrasting the pharmacokinetics of galantamine-ER 
24 mg/day with those of galantamine-IR 12 mg twice daily 
in healthy young subjects.41 Both groups had a lead in period 
of three weeks to escalate to the target dose. The second was 
by means of a population pharmacokinetic model that used 
data from clinical studies with galantamine-IR in AD as 
well as galantamine-ER absorption data to explore whether 
subjects could be switched immediately from twice-daily 
galantamine IR to once daily galantamine ER.42,43 The 
clinical study showed that basic pharmacokinetic parameters 
such as the area under the plasma concentration-time curve 
from time 0 to 24 hours (AUC0–24), mean minimum predose 
plasma concentration (Cmin), and mean plasma concentration 
at steady state (Css) following 7 days of galantamine-ER 
24 mg/day were by and large the same as those found at steady 
state in individuals receiving galantamine IR. The terminal 
elimination half-lives (t½β) of the two formulations were 
also similar. However, not unexpectedly, maximum peak 
plasma drug concentration (Cmax) was higher and the mean 
time to Cmax (tmax) shorter in those receiving galantamine-IR. 
The results were interpreted as indicating that, except for 
the Cmax and tmax, comparable doses of galantamine-ER and 
galantamine-IR were basically bioequivalent. Furthermore, 
the pharmacokinetic model42 predicted no significant differ-
ence in the pharmacokinetics of galantamine-ER on the first 
day of usage compared to galantamine-IR at steady state. 
Therefore, no titration period appeared to be necessary.
Having established the general bioequivalency of 
the two formulations of galantamine, the next step was to 
demonstrate their clinical equivalency. This hypothesis was 
put to the test by the study of Brodaty and colleagues:44 
a 24-week randomized, double-blind, placebo and active-
controlled, multicenter phase III trial, which compared 
galantamine-IR, galantamine-ER and placebo in patients 
with mild to moderate AD (MMSE score range, 10–24). 
The subjects receiving active galantamine were started on a 
total dose of 8 mg/day and titrated, depending on safety and 
tolerability, to 16 or 24 mg/day. Those subjects assigned to 
galantamine-ER received active medication in the morning 
and placebo in the evening.
As in the pivotal trials of galantamine-IR, the primary 
endpoints were; change in cognition (measured by a 
modification of the ADAS-cog, the ADAS-cog11) and global 
rating (CIBIC-plus) from baseline to completion of the trial. 
Secondary endpoints included assessments of behavior 
(the Neuropsychiatric Inventory (NPI)45 and function 
(Alzheimer’s Disease Cooperative Study – Activities of 
Daily Living [ADCS-ADL23]),46 as well as subscores of 
the ADAS-cog11 that assessed memory and non-memory 
neuropsychological domains.
The  results  showed  that  galantamine-ER  and 
galantamine-IR were significantly better than placebo in 
terms of cognition. Both active treatment groups improved 
over the course of the study whereas the placebo group 
declined. By contrast, neither formulation of galantamine was 
significantly different from placebo in terms of the other pri-
mary endpoint, global change, measured by the CIBIC-plus. 
The latter results were different from the pivotal trials of 
galantamine-IR in which drug was superior to placebo 
with regard to CIBIC-plus as well as ADAS-cog scores. An 
intent to treat last observation carried forward analysis of all 
subjects with at least one test score gave results similar to 
those obtained in the observed cases analysis. An exploratory 
post hoc analysis of CIBIC-plus scores stratified in different 
ways revealed only insignificant superiority of galantamine-
ER compared to placebo.47 For the secondary endpoints, 
however, the results indicated that galantamine-ER (but not 
galantamine-IR) recipients declined significantly less than 
placebo recipients on the functional measure over the course 
of the trial. Neither formulation was different from placebo 
in terms of behavior (measure by NPI score).
As for adverse events, there were no significant differ-
ences between the profile of galantamine-ER and that of 
galantamine-IR. In both groups, adverse events occurring in 
five percent or more of patients were mainly related to the 
known cholinergic effects of the drug and consisted of nausea, 
vomiting, anorexia, weight loss, dizziness, and depression. Clinical Interventions in Aging 2010:5 
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As has been noted many times before with the ChEIs, adverse 
events attributed to drug were usually transient and associ-
ated either with the initiation of treatment or the escalation 
of the dose. Minimally more patients on galantamine-ER 
(9%) discontinued treatment because of drug induced adverse 
events compared to those on galantamine-IR (7%). In a post 
hoc analysis48 it was found, however, that among subjects who 
complained of nausea, those on galantamine-ER reported 
significantly fewer days with nausea than those taking 
galantamine-IR. In addition, galantamine-ER recipients 
reported significantly less use of antiemetics.
Although it was perhaps disappointing that neither 
galantamine-ER nor galantamine-IR performed better than 
placebo on the global rating measure, the CIBIC-plus, 
cognitive benefits were clearly demonstrated for both, and 
galantamine-ER was found to be sufficiently similar to 
galantamine-IR to be approved by the FDA and agencies 
in other countries for use in mild to moderate AD. The 
negative findings for global function may simply have been 
due to chance or a consequence of the relatively narrow 
range of scores on the rating instrument. On the other hand, 
the CIBIC-plus is generally considered to have adequate 
psychometric properties, and previous trials of galantamine 
and other ChEIs have shown significant benefit compared to 
placebo using this instrument. In the prescribing information 
prepared by the manufacturer following approval, a starting 
dose of galantamine-ER 8 mg/day, to be raised to an initial 
maintenance dose of 16 mg/day after a minimum of four 
weeks, is recommended.49 Although it is then suggested to 
attempt a further dose escalation to 24 mg/day after at least 
another four weeks,48 the results of the pivotal trial and the 
study of Aronson and colleagues39 do not show statistically 
significant differences between 16 mg and 24 mg/day. Further 
experience is needed to determine how the dose should be 
adjusted with time.
Unfortunately, no other efficacy trials of galantamine-ER 
are available for review. However, two subsequent studies 
looked at other issues involved in the use of galantamine-ER. 
One study showed that the steady state pharmacokinetics of 
the drug are not affected by the co-administration of meman-
tine.50 This is useful information since many AD patients 
receive combination therapy consisting of memantine plus 
a ChEI. The other study, by Scharre and colleagues,50 showed 
that, although a four week titration period, beginning at 
8 mg/day and proceeding to 16 mg/day, is recommended, a one 
week titration might also be tolerable for most patients. The 
latter finding is important because the main issue addressed 
by the development of galantamine-ER was adherence to 
medication regimes. There is now general consensus, based 
on clinical evidence, that treatment with ChEIs, at least for 
limited periods of time, is appropriate in the mild to moderate 
stages of AD.51–56 Although somewhat more difficult to prove, 
there is also at least indirect evidence that long term treatment 
with ChEIs for periods up to 3 to 5 years is also beneficial.57 
Thus, any modification of a medication regime, including a 
shortened titration phase, that will increase compliance must 
be considered a positive development. Indeed, the benefits of 
persistent therapy may go beyond simple clinical improve-
ment or stabilization. Using a special economic model, Caro 
and colleagues58 predicted that persistent use of galantamine 
would delay the need for full time care sufficiently long that 
the cost of galantamine would be more than offset by the 
savings predicted from delaying full time care.
Unfortunately, data also show that AD patients as a group 
do not persist in the use of medication.59,60 Although there 
are undoubtedly many different factors that affect persistence 
of treatment, the particular agent is an important one. In a 
recent study, Herrmann and colleagues60 explored whether 
choice of drug and ease of administration affect persistence 
of therapy with ChEIs. They reviewed a database with infor-
mation on over 5000 elderly individuals who had received a 
new prescription for one of the three standard ChEIs, done-
pezil, rivastigmine, or galantamine, in oral form. When they 
compared one year persistence rates, they found significant 
differences among the different agents. Not only was the 
rate for galantamine-ER (54%) significantly greater than 
that for galantamine-IR (44%), but galantamine-ER had the 
highest 1-year persistence rate of all the drugs evaluated. 
This advantage must, of course, be balanced against other 
factors, including the comparative costs of the different 
formulations, which, are too variable from place to place to 
draw any general conclusion as to the relative benefit.
Although much has been learned in recent years about 
the etiology and pathophysiology of AD, the condition still 
remains in many ways a mystery. Finding the molecular 
and other keys needed to unlock and successfully treat 
this neurodegenerative disease remains a formidable task. 
Therapeutic progress often occurs in fits and starts. Following 
the pace of the 1990s, when four ChEIs and memantine were 
developed and approved for general use in relatively rapid 
succession there has been a lull in the development of new 
treatment modalities for AD. Not unreasonably, most current 
research efforts are directed toward finding future therapies 
that are more effective and thoroughgoing than the ChEIs. 
Yet, there are millions of AD sufferers and their family 
members who are demanding treatment at the present time. Clinical Interventions in Aging 2010:5 
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Although their efficacy is undoubtedly limited, the ChEIs do 
provide at least some temporary, partial benefit. More data 
are needed to assess the impact of galantamine-ER on patient 
compliance, caregiver burden and other important clinical 
outcomes, but if the extended release form of galantamine can 
truly improve patient adherence to treatment, its development 
can only be looked upon as positive and beneficial.
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